Posts Tagged ‘GLP-1 agonists’

When people take a GLP-1 like semaglutide, osteoarthritis often improves. It makes sense. Excess body weight puts a strain on joints, especially the knee. And randomized controlled studies document the clinical benefits. New research confirms what clinical scientists have long suspected. Treating obesity can do more than just relieve the strain of excess weight on […]

Good luck if you want to make sense of headlines about health insurance and coverage trends for GLP-1 medicines. Peruse the headlines and you can find just about any narrative you want. “Rising health premiums push more small business to drop coverage,” according to Inc. “Employers are opting out of covering GLP-1s,” claims Hines, a […]

We are in the midst of what used to be known as diet and weight loss season. And now the Super Bowl is coming up. Instead of diet ads this year, our video feeds are full of ads for telehealth and GLP-1s. Some of them are annoying. But when Serena Williams comes on screen to […]

It is taking a long time for diet culture to fade into oblivion. But we are well down that road when celebrity culture meets obesity science in a new book by Oprah Winfrey and Ania Jastreboff. It’s remarkable, really, that we have come to a time when one of the most iconic persons in the […]

A big change is afoot and the hype is cranking up. With the launch of Wegovy tablets by Novo Nordisk yesterday, we are seeing some very big expectations expressed for a new era in obesity care. The stock market has boosted the value of Novo stock by 15 percent since FDA approved these tablets. Yesterday […]

We do not feel any nostalgia for “diet season.” None. Its demise was apparent two years ago. But in its place, it seems we have a telehealth GLP-1 season. Rebel Wilson is screaming at us to sign up for microdosing with a GLP-1. Put those ads together with somewhat calmer advertising from Ro and Hims, […]

Yet another careful study of shifts in spending on food and restaurant purchases tells us that yes indeed, GLP-1s will likely reshape markets for food. Food systems already feel it and are beginning to adapt. But truthfully, this is probably just a faint, flickering indication of what’s to come. A Careful Analysis of Food Purchasing […]

It is no secret that alcohol use disorder is a risk after metabolic and bariatric surgery. The risk rises as time passes after surgery, with one study finding three percent of patients followed for a median of six years having one alcohol use disorder diagnosis in their medical records. Another study found that three years […]

We strongly suspect that advanced oral obesity medicines may be a defining milestone for 2026. This is because they have the potential to fill an important gap in obesity therapy – the unmet need for therapies that people can persistently take to maintain control of this chronic disease. Late yesterday, FDA granted approval for the […]

This has been quite a year. Many remarkable changes we’ve witnessed go well beyond the scope of this commentary. In the policy realm, some of them are close at hand. CDC, which has long guided health policy on obesity, nutrition, and physical activity, has been decimated. NIH is under extraordinary stress. But on the positive […]